Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

225.50CHF
16 Feb 2018
Change (% chg)

CHF2.10 (+0.94%)
Prev Close
CHF223.40
Open
CHF225.00
Day's High
CHF226.30
Day's Low
CHF224.00
Volume
2,068,604
Avg. Vol
1,964,378
52-wk High
CHF273.00
52-wk Low
CHF214.30

Latest Key Developments (Source: Significant Developments)

Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis
Thursday, 15 Feb 2018 08:00am EST 

Feb 15 (Reuters) - Roche Holding Ag ::HEALTH CANADA APPROVES OCREVUS® (OCRELIZUMAB) FOR CANADIANS LIVING WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS).‍ROCHE CANADA- HEALTH CANADA HAS APPROVED OCREVUS UNDER PROVISIONS MADE WITHIN ITS NOTICE OF COMPLIANCE WITH CONDITIONS POLICY​.  Full Article

Roche says FDA Grants Priority Review For Mabthera/ Rituxan For Pemphigus Vulgaris
Wednesday, 14 Feb 2018 01:15am EST 

Feb 14 (Reuters) - Roche Holding AG ::ROCHE HOLDING AG - FDA GRANTS PRIORITY REVIEW FOR ROCHE’S MABTHERA/ RITUXAN (RITUXIMAB) FOR PEMPHIGUS VULGARIS.  Full Article

Roche Receives FDA Clearance For Factor Ii And Factor V Test On The Cobas® 4800 System
Tuesday, 13 Feb 2018 02:05pm EST 

Feb 13 (Reuters) - Roche Holding Ag ::ROCHE RECEIVES FDA CLEARANCE FOR FACTOR II AND FACTOR V TEST ON THE COBAS® 4800 SYSTEM.  Full Article

Roche Says Late-stage Study Shows Genentech's Tecentriq And Avastin Reduced The Risk Of Disease Worsening Or Death By 26 Pct In Certain People With Advanced Kidney Cancer
Monday, 5 Feb 2018 05:00pm EST 

Feb 5 (Reuters) - Roche Holding Ag ::PHASE III IMMOTION151 STUDY SHOWED GENENTECH’S TECENTRIQ (ATEZOLIZUMAB) AND AVASTIN (BEVACIZUMAB) REDUCED THE RISK OF DISEASE WORSENING OR DEATH BY 26 PERCENT IN CERTAIN PEOPLE WITH ADVANCED KIDNEY CANCER.GENENTECH SAYS TECENTRIQ AND AVASTIN MET CO-PRIMARY ENDPOINT.GENENTECH - INITIAL OBSERVATIONS FROM CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN OVERALL STUDY POPULATION WERE "ENCOURAGING, BUT ARE STILL IMMATURE".GENENTECH - RATE OF TREATMENT-RELATED GRADE 3-4 ADVERSE EVENTS LOWER WITH TECENTRIQ & AVASTIN COMBINATION VERSUS SUNITINIB IN ALL TREATED PATIENTS.  Full Article

Roche CEO Says 2018 Growth Forecast Is More Cautious Than 2017 Targets, But Company 'Clearly' Expects To Grow Despite Biosimilar Erosion
Thursday, 1 Feb 2018 11:39am EST 

Feb 1 (Reuters) - Roche ::CEO SAYS 2018 GROWTH FORECAST IS MORE CAUTIOUS THAN 2017 TARGETS, BUT COMPANY 'CLEARLY' EXPECTS TO GROW DESPITE BIOSIMILAR EROSION.  Full Article

Roche Drugs Chief Says Erosion In European Rituxan Sales To Intensify In 2018 As Biosimilars Enter More Markets After 26 Percent 4th Quarter Drop
Thursday, 1 Feb 2018 11:38am EST 

Feb 1 (Reuters) - Roche ::DRUGS CHIEF SAYS EROSION IN EUROPEAN RITUXAN SALES TO INTENSIFY IN 2018 AS BIOSIMILARS ENTER MORE MARKETS AFTER 26 PERCENT 4TH QUARTER DROP.  Full Article

Roche Holding AG Drugs Chief Says Immunotherapy Competitors Taking Share From Avastin
Thursday, 1 Feb 2018 04:06am EST 

Feb 1 (Reuters) - Roche Holding Ag ::CFO SAYS EXPECTS HIGH THREE DIGIT MILLION TAX BENEFIT FROM U.S. TAX REFORM.CEO SAYS U.S. TAX REFORM HAS BOOSTED U.S. COMPETITIVENESS.DRUGS DIVISION CHIEF SAYS OCREVUS HAS 5 PERCENT MULTIPLE SCLEROSIS MARKET SHARE AFTER THREE QUARTERS OF SALES, SEES NO SLOWING IN UNITED STATES.CEO EXPECTS OCREVUS TO "EASILY" EXCEED 1 BILLION SFR IN SALES IN 2018.DRUGS CHIEF EXPECTS SIMILAR EROSION FOR HERCEPTIN AS RITUXAN AS BIOSIMILARS ENTER MARKET.DRUGS CHIEF SAYS IMMUNOTHERAPY COMPETITORS TAKING MARKET SHARE FROM AVASTIN IN U.S. LUNG CANCER TREATMENT, RESULTING IN REVENUE DECLINE.  Full Article

Roche Holding AG CEO Says No Change In M&A Strategy
Thursday, 1 Feb 2018 01:55am EST 

Feb 1 (Reuters) - Roche Holding Ag ::CEO SAYS CONFIDENT NEW DRUGS CAN COMPENSATE FOR OLDER DRUGS LOSING PATENT PROTECTION.CEO SAYS ROCHE CAN POTENTIALLY SLIGHTLY GROW BUSINESS DESPITE BIOSIMILARS, INTENDS TO KEEP 'STRONG MARGINS WHICH WE ENJOY TODAY'.CEO SAYS HAS INCREASING CONFIDENCE OVER RECENT PAST THAT ROCHE CAN COMPENSATE FOR BIOSIMILARS.CEO SAYS IMPAIRMENT CHARGES ON SEVERAL ITEMS INCLUDING ESBRIET, DUE TO "MODERATE UPTAKE" IN EARLIER LINES OF TREATMENT.CEO SAYS VERY CONFIDENT TECENTRIQ TO PLAY LEADING ROLE IN VARIOUS CANCER TYPES.CEO SAYS NO CHANGE IN M&A STRATEGY, LOOKING FOR BOLT-ON OPPORTUNITIES TO COMPLEMENT PORTFOLIO.  Full Article

Forty Seven Inc Says Announced Deal With Genentech To Collaborate On Novel Immuno-Oncology Combination For Leukemia, Bladder Cancer
Thursday, 11 Jan 2018 07:30am EST 

Jan 11 (Reuters) - Roche Holding Ag ::FORTY SEVEN INC SAYS ANNOUNCED DEAL WITH GENENTECH TO COLLABORATE ON NOVEL IMMUNO-ONCOLOGY COMBINATION FOR LEUKEMIA, BLADDER CANCER.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

PRESS DIGEST- Wall Street Journal - Feb 16

Feb 16 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.